Company intelligence / Profile preview
Grand Shuyang Life Sciences
Chengdu, Sichuan, China
- Ownership
- Private
- Employees
- ~2000
- Development stage
- Other
01
Overview
KN057, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI) for hemophilia treatment, received FDA Orphan Drug Designation in 2024 and is in two Phase III clinical trials in China. The product is a highly concentrated liquid formulation with long half-life and once-weekly subcutaneous injection, designed to improve compliance and reduce bleeds in hemophilia patients.
- Therapeutic areas
- HematologyOtherDermatologyInfectious DiseasesGastroenterology
- Modalities
- ProteinMonoclonal antibodyRecombinant proteinVaccine
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Neoletix (Beijing) - exclusive license agreement for human recombinant factor VIII (NX01) in Greater China region
Beyond the preview
Go deeper on Grand Shuyang Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grand Shuyang Life Sciences.